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Because of the popularity of Echinacea as a dietary supplement, researchers have been actively
investigating which Echinacea constituent or groups of constituents are necessary for immune-
modulating bioactivities. Our prior studies indicate that alkylamides may play an important role in the
inhibition of prostaglandin E2 (PGE2) production. High-performance liquid chromatography fractionation,
employed to elucidate interacting anti-inflammatory constituents from ethanol extracts of Echinacea
purpurea, Echinacea angustifolia, Echinacea pallida, and Echinacea tennesseensis, identified fractions
containing alkylamides and ketones as key anti-inflammatory contributors using lipopolysaccharide-
induced PGE2 production in RAW264.7 mouse macrophage cells. Nitric oxide (NO) production and
parallel cytotoxicity screens were also employed to substantiate an anti-inflammatory response.
E. pallida showed significant inhibition of PGE2 with a first round fraction, containing gas chromato-
graphy-mass spectrometry (GC-MS) peaks for Bauer ketones 20, 21, 22, 23, and 24, with 23 and 24
identified as significant contributors to this PGE2 inhibition. Chemically synthesized Bauer ketones 21
and 23 at 1 μM each significantly inhibited both PGE2 and NO production. Three rounds of fractionation
were produced from an E. angustifolia extract. GC-MS analysis identified the presence of Bauer ketone
23 in third round fraction 3D32 and Bauer alkylamide 11 making up 96% of third round fraction 3E40.
Synthetic Bauer ketone 23 inhibited PGE2 production to 83% of control, and synthetic Bauer alkylamide
11 significantly inhibited PGE2 and NO production at the endogenous concentrations determined to be
present in their respective fraction; thus, each constituent partially explained the in vitro anti-inflam-
matory activity of their respective fraction. From this study, two key contributors to the anti-inflammatory
properties of E. angustifolia were identified as Bauer alkylamide 11 and Bauer ketone 23.
KEYWORDS: Echinacea purpurea; Echinacea angustifolia; Echinacea pallida; prostaglandin E2; nitric
oxide; Bauer alkylamides; Bauer ketones; anti-inflammatory; fractionation
INTRODUCTION
Sales of Echinacea as a botanical supplement have remained
high over recent years in theUnitedStates, reaching approximately
21 million dollars in 2005 (1). The efficacy and health benefits of
taking Echinacea as a supplement have yet to be verified scienti-
fically, and researchers are still unclear as to how the constituents
of Echinacea act individually or in concert to elicit the bioactive
properties that have been observed in numerous studies, both in
vitro and in vivo (2, 3). Although Echinacea extracts are complex
mixtures consisting of several constituents, alkylamides and caffeic
acid derivatives have received considerable attention recently for
their abilities to modulate the immune system. Recent studies have
shown that alkylamides of Echinacea are partially responsible for
anti-inflammatory responses such as inhibition of prostaglandin
E2 (PGE2), TNF-R, and nitric oxide (NO) production in
RAW264.7 mouse macrophage cells (2-5), as well as inhibition
of cyclooxygenase activity in neuroglioma cells and other in vitro
model systems (4, 6). Studies have further validated that alkyla-
mides are capable of binding to and activating the cannabinoid
receptor type 2, providing insight into the mechanism by which
these constituents may modulate immune function (7, 8). Caffeic
acid derivatives have been associated with antiviral and anti-
oxidant properties (9-11). It has been hypothesized that alkylamides
*To whom correspondence should be addressed. Tel: 515-294-9873.
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and caffeic acid derivatives interact, perhaps synergistically, with
each other or other compounds to elicit immunomodulatory
effects (9).
PGE2 is a major lipid mediator of inflammation that is
produced through the activation of the arachidonic acid cascade,
via the enzymatic activity of the cyclooxygenase isoforms. The
inducible nature of PGE2 production when macrophage cells are
stimulated by lipopolysaccharide (LPS) makes this eicosinoid an
ideal target for measuring an inflammatory response in vitro.
Our studies were conducted to identify Echinacea constituents
that are responsible for the previously described PGE2 inhibi-
tion (2). Methods have been developed to quantitatively deter-
mine the amount of alkylamides and caffeic acid derivatives
present in different parts of the Echinacea plant using reverse-
phased high-performance liquid chromatography (HPLC) and
gas chromatography-mass spectrometry (GC-MS) analysis
(12, 13). Semipreparative reverse-phased HPLC was utilized to
fractionate Echinacea extracts into fractions and subfractions
that separate phytochemicals according to their hydrophobic
properties, concentrating a reduced number of constituents to
analyze for anti-inflammatory potential. Eluents from HPLC
fractionations were monitored for absorbance at wavelengths of
260 and 330 nm to identify lipophilic alkylamides and phenolic
compounds, such as caffeic acid derivatives. Further fractiona-
tion was guided by identifying fractions capable of inhibiting
PGE2 production, allowing for a thorough investigation into the
hypothesized synergistic or additive interactions that are thought
to occur among the constituents of Echinacea extracts and allow
for the identification of key anti-inflammatory constituents
through the use of GC-MS analysis. To have a more complete
view of how interacting constituents found in Echinacea inhibit
inflammatory mediators, NO production was also assessed in
RAW264.7macrophage cells treated with chemically synthesized
phytochemicals, which were identified to be important in the
PGE2 assay with Echinacea angustifolia.
MATERIALS AND METHODS
Safety. LPS compounds are pyrogenic and should not be inhaled or
allowed to enter the bloodstream.
PlantMaterial and Extraction. Plantmaterials were provided by the
U.S. Department of Agriculture North Central Regional Plant Introduc-
tion Station (NCRPIS, Ames, IA). E. angustifolia (PI631285), Echinacea
purpurea (PI631307), Echinacea pallida (PI631293), and Echinacea tennes-
seensis (PI631250) were used for the semipreparative HPLC fractionation.
Root material from each species was collected as previously described (2)
from a 2005 or 2006 harvest. Further information about the accessions can
be found on the Germplasm Resources Information Network database at
http://www.ars-grin.gov/npgs/acc/acc_queries.html provided byNCRPIS.
Plant materials were stored at -20 C under nitrogen in zip-lock bags
prior to use. The Echinacea plant materials were all dried root powders.
They were previously washed and then completely dried at 40 C forced
air conditions, followed by grinding through a 40-mesh screen Wiley
grinder (14).
For each accession, 6 g of Echinacea root material was extracted with
95% ethanol and 5% endotoxin-free water using a Soxhlet apparatus for
6 h for exhaustive extraction, following the protocol created by Liu (15).
To avoid endotoxin contamination, the glassware was heated to 180 C for
at least 2 h prior to use. After the extraction, the 95% aqueous ethanol
solvent was evaporated using a Rotavap (Buchi rotavaps model R-144,
R-110, R-111, and R-200, Switzerland) to obtain the dried extract, which
was weighed. The dried extracts were redissolved in endotoxin-free water,
and ethanol was added at a ratio of 1:3 (water:ethanol) to obtain a
concentration of no more than 0.6 g of extracted material/mL for a 5 mL
injection through the semipreparative HPLC fractionation. The extracts
were stored at -20 C overnight prior to fractionation.
Semipreparative HPLC Fractionation. The 95% ethanol extracts
of Echinacea were filtered through a 0.45 μm filter prior to injection into
the semipreparative HPLC system consisting of two Beckman model 110B
pumps controlled by a Module406 Beckman System Gold Analogue
Interface (Beckman Coulter, Fullerton, CA) using a YMC-PACK ODS-
AM 250 mm  10 mm I.D. s-5 μm, 12 nm reversed-phase C18 columns
(Waters Corp.) and a 5mL loop on aRheodynemodel 7010 injection valve.
Fractionation was conducted with a solvent gradient designed with
acetonitrile as solvent B and 0.1% HPLC grade glacial acetic acid in
endotoxin-freeMilli-Q water as solvent A. The gradient started at 10%B,
with a flow rate of 3mL/min, and increased to 30%B in 30min.At 30min,
the gradient increased to 90% B over 50 min. At 80 min, the gradient
increased to 100% B in 10 min. The gradient was held at 100% B for
20min.Fraction1was collected in the first 30minof the gradient. Fraction
2 was collected between 30 and 40 min, fraction 3 was collected between
40 and 80 min, fraction 4 was collected between 80 and 90 min, and
fraction 5 was collected between 90 and 110 min. Second round fractions
were generated by collecting at 1 min intervals across the same gradient
profile within bioactive fractions. For bioassay purposes, subfractions of
E. angustifolia fraction 3 (3A, 3B, 3C, 3D, and 3E) were created by pooling
8 min intervals across the 40min of fraction 3. For example, 3B represents
eluent collected betweenmin 9 andmin 16within fraction 3 (or atmin 49 to
min 56 of gradient time). The third round fractions were then collected at
1 min intervals. For example, fraction 3D28 was the 3 mL fraction col-
lected at 28 min into fraction 3 (or at min 68 of gradient time). The
fractions and subfractionswere dried, first by removal of the organic phase
by rotary evaporation and second by the amount ofwater by freeze drying.
Compounds in first round fractions of all Echinacea species and second
round fractions produced fromE. angustifoliawere identified usingHPLC
as compared to synthetic standards. The literature has shown that
alkylamides dissolved in liquid form and stored at-20 C are stable over
extended periods of time (15-17). Therefore, all fractions were diluted in
dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO) and stored at-20 C
to maintain the stability of alkylamides and thawed at room temperature
in preparation for analysis.
HPLC Analysis of E. angustifolia Second Round Fractions.
HPLC analysis and quantification of constituents found in second round
fractions of E. angustifolia were performed as previously described (2).
GC-MS Analysis. GC-MS analyses were performed using an Agilent
Technologies (Palo Alto, CA) gas chromatograph (6890 series), equipped
with a model 5973 mass detector operating in the electron impact
ionization mode (70 eV). The analyses were carried out by injecting in
splitless mode. Analytes were separated using an Agilent Technologies
capillary column (HP-5MS fused silica column coated with 5% diphenyl
95% dimethyl polysiloxane, with the dimensions 30 m length  250 μm
bore, 0.25 μm film thickness). Helium was used as the carrier gas at the
flow rate of 1.2 mL/min. Identification of compounds was facilitated by
using the Agilent Technologies enhanced ChemStation Software, version
D.02.00.275.
Alkylamide and Ketone Synthesis. Alkylamide synthesis was con-
ducted as described previously (2). Ketones were chemically synthesized
according to the procedures outlined by Kraus et al. (18) and in the thesis
of Jaehoon Bae (19). Alkylamide and ketone concentrations were calcu-
lated after correcting for percent purity, yielding concentrations equivalent
to 100% pure synthetic constituent. The calculated percent purity before
correction for Bauer alkylamide 10was 82%, for Bauer alkylamide 11 was
92%, for Bauer ketone 20 was 82%, for Bauer ketone 21 was 76%, for
Bauer ketone 23 was 90%, and for Bauer ketone 24was 99%.All synthetic
alkylamides and ketones were stored at -80 C under argon gas.
Cell Culture. The cell culture model used for these studies was
RAW264.7 mouse monocyte/macrophage cells that were obtained from
American Type Culture Collection (cat: TIB-71; Manassas, VA). All cul-
turing conditions and procedures were previously described by Hammer
et al. (20) with the exception of maintaining optimal growth conditions at
95% humidity.
Measurement of PGE2. PGE2 production was analyzed using
PGE2 enzyme immunoassay (GE Biosciences, Piscataway, NJ) after
treating RAW264.7 mouse macrophage cells for 8 h with fractions from
E. angustifolia, E. purpurea, E. pallida, and E. tennesseensis and with or
without LPS (Escherichia coliO26:B6, Sigma) as previously described (2).
Quercetin (3,5,7,30,40-pentahydroxy flavon), a common flavonoid found
inmany plant species includingEchinacea, was used as the positive control
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at a concentration of 10 μM (Sigma). Also, baicalein (5,6,7-trihydroxy-
flavone), a flavonoid found in the medicinal herb Scutellaria baicalensis,
was used as a positive control at a concentration of 6 μM (synthesized by
G. A. Kraus’s laboratory at Iowa State University).
Measurement of NO Production. NO production was analyzed
using Griess Reagent System (Promega) following the manufacturer’s
protocol. RAW264.7 cells were plated at a density of 1.57 105 cells/well
in a 24-well cell culture plate and incubated overnight. Chemically
synthesized ketones of Echinacea and combinations of alkylamides and/
or ketones were then added to the cells either with or without LPS for a
24 h time period. Each treatment contained four controls, which were
media, media þ DMSO (vehicle control), media þ LPS, and media þ
DMSOþ LPS. Quercetin was used as the positive control at a concentra-
tion of 10 μM (Sigma). After the 24 h treatment period, the cell super-
natants were collected and stored at 4 C until used in the NO assay.
Cytotoxicity of Echinacea Fractions. The method used to detect
cytotoxicity was previously described by LaLone et al. (2) using the
Celltiter96 Aqueous One Solution Cell Proliferation Assay (Promega
Corp., Madison, WI). Cytotoxicity analysis was carried out for all
fractions from all Echinacea species analyzed. Each fraction was screened
for cytotoxicity at concentrations comparable to those used in the PGE2
assay and incubated for 24 h. Ursolic acid (Fisher Scientific, Hanover
Park, IL) was used as the positive control at three concentrations, 10, 30,
and 50 μM, with significant cytotoxicity identified at the two highest
concentrations. Synthetic Bauer alkylamide 11 and Bauer ketone 23 were
also screened for cytotoxicity after incubation with macrophages for 72 h.
Statistical Analysis. Both log transformed PGE2 data and NO data
were analyzed using randomized complete block design with variable levels
of treatment, followedby a t test basedonpooled error variance to determine
statistical significance as compared to the mediaþDMSOþ LPS control.
In all figures, the data are represented as % of control ( standard error,
normalizing the media þ DMSO þ LPS control to 100% PGE2 or NO
production within each block and summarizing across all blocks to obtain
the mean and standard error. The three subsamples of cytotoxicity values in
each block were averaged before analysis as a randomized complete block
design as above. The cytotoxicity data are also presented as % of control(
standard error, normalizing the media þ DMSO control to 100% cell
survival. All statistical analysis was conducted using theGLMprocedures in
SAS (version 9.1, SAS Institute Inc., Cary, NC).
RESULTS
Fractions from E. pallida, E. purpurea, and E. tennesseensis
Inhibit PGE2 Production. To elucidate key constituents capable of
inhibiting select inflammatory mediators, a Soxhlet ethanol ex-
tract of E. pallida was fractionated into five fractions, and each
was assessed for its effect on PGE2 production in RAW264.7
mouse macrophage cells. The analysis yielded one fraction,
fraction 3, capable of significantly inhibiting PGE2 production
(36.8% of control) at a concentration of 5 μg/mL (Figure 1).
Another interesting observation was that fraction 3, at a concen-
tration of 5 μg/mL, inhibited PGE2 production to a greater extent
than the initial ethanol extract of E. pallida at a concentration of
25 μg/mL, indicating the importance of enriching selected con-
stituents and separating them from others using fractionation.
When fraction 3 from E. pallida was diluted from 5 to 1 μg/mL,
inhibition of PGE2 production was still observable (71.2% of
control, p=0.07). In a parallel cytotoxicity study, it was deter-
mined that the fractions from E. pallida were not cytotoxic to the
RAW264.7 mouse macrophage cells, indicating that cell death
could not account for the observed inhibition of PGE2 production
(Figure 1). GC-MS analysis indicated that fraction 3 contains
numerous constituents, including Bauer ketones 20, 21, 22, 23,
and 24 (Figure 2A). Quantification of Bauer ketones, 20, 21, 23,
and 24 present in fraction 3 yielded concentrations of 0.7, 0.6, 2.6,
and5μM,respectively.Combinations ofquantifiedBauer ketones
were analyzed for their ability to inhibit PGE2 production
(Figure 2B). This analysis indicated that Bauer ketones 23 and
24 were the most important of the identified ketones in partially
explaining the PGE2 inhibitory capabilities of fraction 3 from
E. pallida. Chemically synthesized Bauer ketones 20, 21, and 23,
which are constituents of E. pallida ethanol extracts and HPLC-
generated fractions (Figure 3A), were analyzed for their ability to
inhibit PGE2 production and NO production at three concentra-
tions (5, 2.5, and 1 μM) to determine if they played a key role in
the significant inhibition of PGE2 identified with fraction 3. It
was determined that Bauer ketones 21 and 23 were capable of
significant inhibition of PGE2 (p<0.05) and NO (p<0.0001)
production at a concentration as low as 1 μM (Figure 3B).
Fractionation of a Soxhlet ethanol extract of E. purpurea
yielded seven fractions, none of which were able to significantly
inhibit PGE2 production, and none were found to be cytotoxic
(Table 1).
A Soxhlet ethanol extract of E. tennesseensis, which is a less-
studied species, was fractionated into five fractions by reverse phase
HPLC to identify PGE2 inhibitory capabilities. Fraction 3, contain-
ingBauer alkylamides 12, 13, 14, 16, and17,was able to significantly
inhibit PGE2 at a concentration of 41 or 20 μg/mL, but when the
fraction was diluted to 5 μg/mL, its inhibitory ability was lost
(Table 1). The initial ethanol extract (59μg/mL) andHPLC fraction
5 (23 μg/mL) of E. tennesseensis were significantly cytotoxic to the
RAW264.7 cells, but because of their inability to significantly inhibit
PGE2 production, further dilutions were not carried out.
Three Rounds of Bioactivity Guided Fractionation of an
E. angustifolia Ethanol Extract. Inhibition of PGE2 production
was used to guide three rounds of HPLC fractionation initiated
with a Soxhlet ethanol extract of E. angustifolia. Figure 4 out-
lines the fractionation scheme. The first round of fractionation
produced five fractions. The alkylamide-rich fraction 3, from
E. angustifolia, was shown to significantly inhibit PGE2 produc-
tion (51.1% of control) at a concentration as low as 1 μg/mL
(Figure 5). Although fraction 4 had the ability to significantly
inhibit PGE2productionat a concentrationof 16μg/mL, it proved
to be significantly cytotoxic for the RAW264.7 cells. Therefore,
fraction 3 was identified for further rounds of fractionation.
The second round of fractionation, initiated with fraction 3
from the previous round, yielded five second round fractions
Figure 1. Fraction 3 from a 2005 extract of E. pallida (PI631293)
significantly inhibited PGE2 production in RAW264.7 cells. The black bars
represent PGE2 levels after induction with 1 μg/mL LPS and treatment with
an Echinacea fraction or ethanol extract (n = 3). All treatmentsþ LPS were
compared to mediaþ DMSOþ LPS control that was set at 100% (2.0 ng/
mL). Treatments were also performed without LPS induction showing no
significant reduction in PGE2 production (pg 0.21). The treatments without
LPS were compared to the media þ DMSO control set at 100% (0.2 ng/
mL). Media alone did not inhibit PGE2 production (104% of control).
Baicalein and quercetin were used as positive controls and showed
significant inhibition of PGE2 production (p < 0.001). Parallel cytotoxicity
screens were conducted yielding no significant cytotoxicity with any of the
E. pallida fractions (data not shown). * and ** are representative of p < 0.05
and p < 0.001. Each bar represents % of control ( standard error.
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labeled 3A-3E. Of these, fractions 3D and 3E, at a concentration
of 5 μg/mL, significantly inhibit PGE2 production at 47.1 and
38.6% of control, respectively, without any obvious cytotoxi-
city (Figure 6A). HPLC analysis of 0.15 mg second round
fractions 3D and 3E led to the detection of several alkylamides
(as detected by absorbance at 260 nm) in fraction 3D (Figure 6B)
and identification of Bauer alkylamides 10 and 11 in fraction 3E
(Figure 6C). Concentrations of Bauer alkylamides 10 and 11were
estimated in fraction 3E from the HPLC analysis at 5.62 and
9.48 μM, respectively (Table 2). PGE2 production was analyzed
to determine whether these chemically synthesized Bauer alkyl-
amides, individually or in combination at the concentrations
detected in fraction 3E, were able to explain the inhibition of
PGE2 production observed with fraction 3E. The combination of
Bauer alkylamides 10 and 11 at the concentrations detected by the
HPLC analysis of fraction 3E inhibited PGE2 production 82.6%
of control, which indicates therefore that the two alkylamides
could not be the sole components responsible for the observed
bioactivity of fraction 3E (Figure 7). In these experiments, cell
viability was not significantly different than the media þDMSO
control. It was interesting to note that synthetic Bauer alkyl-
amides 10 and 11, when screened alone in the PGE2 production
assay, were significantly inhibitory at the concentrations found in
fraction 3E, but additive effects were not detected in the PGE2
production screen. The combination of alkylamides found in
fraction 3D was not carried out as fraction 3E was more effective
at inhibiting PGE2 production, and there were several other
alkylamides identified in fraction 3D, many of which are not
synthetically available.
A third round of HPLC fractionation was carried out starting
with the material from second round fractions 3D and 3E to
further elucidate key constituents found in E. angustifolia that
contribute to the inhibitionof PGE2 production. Fractionation of
fractions 3D and 3E each produced eight fractions labeled
fractions 3D25-3D32 and fractions 3E33-3E40, respectively.
One of these, fraction 3D32, was significantly inhibitory of PGE2
production (44.9% of control) at a concentration of 1 μg/mL
(Figure 8A). The fractionation of fraction 3E produced two
fractions that significantly inhibited PGE2 production at a con-
centration of 1 μg/mL, fraction 3E33 that inhibited PGE2
production at 14.1% of control, and fraction 3E40 that inhibited
PGE2 production at 18.4% of control (Figure 8B). These third
round fractions were not significantly cytotoxic to theRAW264.7
mouse macrophage cells.
GC-MS Analysis of Selected Third Round E. angustifolia Frac-
tions. Selected fractions from the third round fractionation of
E. angustifolia were analyzed by GC-MS based on their activity
in the PGE2 production assay (Table 3). Fractions 3D32, 3E33,
and 3E40 were selected for GC-MS analysis due to their ability
to significantly inhibit PGE2 production at a concentration of
Figure 2. (A) GC-MS chromatogram of fraction 3 from E. pallida, identifying key ketones. All identified constituents were confirmed via synthetic standards.
(B) Significant inhibition of LPS-induced PGE2 production in RAW264.7 cells after treatment with chemically synthesized Bauer ketones at concentrations
present in fraction 3 from E. pallida. The black bars represent PGE2 levels after induction with 1 μg/mL LPS and treatment with an Echinacea fraction or
synthetic Bauer ketone (n = 3). All treatmentsþ LPSwere compared tomediaþDMSOþ LPS control that was set at 100% (5.6 ng/mL)with the combination
of Bauer ketones 21, 23, and 24 showing significant reduction of PGE2 production (p = 0.032). Treatments were also performed without LPS induction and
compared to the mediaþ DMSO control set at 100% (0.03 ng/mL), and no significant changes were observed with any of the treatments in this comparison.
Media alone did not inhibit PGE2 production (99%of control). * and ** are representative of p < 0.05 and p< 0.001. Each bar represents%of control( standard
error. Quercetin was used as the positive control.
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Figure 3. (A)Structures andnomenclature for Bauer ketones identified in fraction 3 fromE. pallida. (B) Significant inhibition of LPS inducedPGE2andNOproduction
inRAW264.7 cells after treatmentwith chemically synthesizedBauer ketones 21and23. Theblack bars represent PGE2 levels, and thewhite bars representNO levels
after induction with 1 μg/mL LPS and treatment with a ketone (n = 3). All treatmentsþ LPSwere compared tomediaþ DMSOþ LPS control that was set at 100%
PGE2 production (3.7 ng/mL) and NO production (12.4 ng/mL). Treatments were also performed without LPS induction showing significant reduction of PGE2
production with Bauer ketone 21 at 1 μM (p = 0.046). The treatments without LPS were compared to the media þ DMSO control set at 100% PGE2 production
(0.02 ng/mL). There was no significant difference in NO production in treatments without LPS. Quercetin was used as a positive control for both studies and showed
significant inhibition of PGE2 andNOproduction (p<0.0001). * and ** are representative of p<0.05 and p<0.001. Each bar represents%of control( standard error.
Parallel cytotoxicity screens were conducted yielding no significant cytotoxicity with any of the chemically synthesized Bauer ketones (data not shown).
Table 1. Inhibition of LPS-Induced PGE2 Production and Cytotoxicity Analysis after Treatments with E. purpurea and E. tennesseensis Fractions
a
anti-inflammatory (PGE2) cytotoxicity
species fraction accession concentration (μg/mL) % of control ( SE p value concentration (μg/mL) % control ( SE p value
E. purpurea fraction 1 PI631307 274 122( 22 0.62 274 101( 2 0.81
E. purpurea fraction 2 PI631307 89 134( 10 0.38 89 98( 3 0.49
E. purpurea fraction 3 PI631307 75 65( 21 0.08 75 105( 2 0.23
E. purpurea fraction 4 PI631307 41 112( 11 0.75 41 98( 4 0.56
E. purpurea fraction 5 PI631307 95 118( 21 0.68 95 96 ( 2 0.33
E. purpurea fraction 6 PI631307 96 123( 15 0.56 96 101( 4 0.87
E. purpurea fraction 7 PI631307 23 137( 39 0.53 23 94( 1 0.14
E. purpurea ethanol extract PI631307 25 48( 13 0.02 25 105( 4 1.0
E. tennesseensis fraction 1 PI631250 271 87( 9 0.48 577 94( 3 0.11
E. tennesseensis fraction 2 PI631250 0.3 109( 11 0.72 0.3 96( 5 0.30
E. tennesseensis fraction 2 PI631250 0.14 104( 13 0.91
E. tennesseensis fraction 3 PI631250 41 6( 2 <0.0001 41 96( 3 0.77
E. tennesseensis fraction 3 PI631250 20 24( 10 <0.0001
E. tennesseensis fraction 3 PI631250 5 90( 21 0.48
E. tennesseensis fraction 4 PI631250 8 119( 4 0.43 17 97( 3 0.38
E. tennesseensis fraction 5 PI631250 11 128( 14 0.28 23 89( 3 0.01
E. tennesseensis ethanol extract PI631250 25 89( 9 0.56 59 89( 1 0.01
aHPLC was used to fractionate a 2005 extract of E. purpurea (PI631370) and a 2006 extract of E. tennesseensis (PI631250), yielding no significant inhibition of PGE2
production at concentrations lower than 20 μg/mL. All treatments were compared to mediaþ DMSO control that was set at 100% for both PGE2 analysis and cytotoxicity. For
E. purpurea and E. tennesseensis, 100% of control for PGE2 was 1.7 and 2.8 ng/mL, respectively. Baicalein (6 μM) was the positive control for the PGE2 assay, and ursolic acid
(10, 30, and 50 μM) was the positive control for the MTS cytotoxicity assay. Each fraction or extract represents three replicates ( standard error for both the PGE2 and the
cytotoxicity analyses. Cytotoxicity was not performed on dilutions of fractions when the higher concentrations were not cytotoxic. Bolded p value indicates significance.
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1 μg/mL. Two fractions, fractions 3D28 and 3E38, were also
selected for further analysis because they were fractions that did
not significantly inhibit PGE2 production. These analyses deter-
mined that Bauer ketone 23 is a major constituent of fraction
3D32, occurring at a concentration of 0.83 μM. Bauer ketone 23
and Bauer alkylamide 10 were detected in 1 μg/mL of fraction
3E33 at concentrations of 0.15 and 0.25 μM, respectively, and
Bauer alkylamide 11 was quantified to be present at a concentra-
tion of 3.55 μM in fraction 3E40.
Combinations of synthetic constituents and individual syn-
thetic constituents, identified to be present through GC-MS
analysis of these third round HPLC fractions, were screened for
their ability to modulate PGE2 and NO production at the
concentrations present in their respective third round fractions.
Synthetic Bauer ketone 23 was shown to significantly inhibit
PGE2 and NO production previously at a concentration of 1 μM
(Figure 3B), and after further dilution of Bauer ketone 23 to the
concentration of 0.83 μM inhibition of PGE2, production re-
mained significant, whereas NO production was not significantly
inhibited (55.2 and 68.2% of control, respectively) (Figure 9 for
PGE2 data). Bauer ketone demonstrated no cytotoxicity after
incubation for 72 h (109.1% of control). Synthetic Bauer alkyla-
mide 11, at a concentration of 3.55 μM, significantly inhibited
PGE2 production (70.6% of control) andNOproduction (75.1%
of control) (Figure 10) without any cytotoxicity after a 72 h
incubation (94.1% of control). The combination of synthetic
Bauer alkylamide 10 and Bauer ketone 23 did not inhibit PGE2
production at the concentrations present in fraction 3E33 (121.0%
of control). Neither synthetic Bauer ketone 23 alone nor the
combination of Bauer alkylamide 10 and Bauer ketone 23 at the
concentrations present in the respective bioactive fractions signifi-
cantly modulated NO production or cell viability (p g 0.09).
Although identified alkylamides and ketones found in these
bioactive fractions were stable under our storage and experimental
Figure 4. Semipreparative reverse-phased HPLC fractionation scheme of E. angustifolia extract from 2006 harvest (PI631285). Bolded fractions represent
those showing significant inhibition of LPS-induced PGE2 production. Numbers in parentheses indicate % of control( standard error of PGE2 production as
compared to the mediaþ DMSOþ LPS control set at 100% PGE2 production. * and ** are representative of p < 0.05 and p < 0.001. See Figures 4-8 for
details on PGE2 data including concentrations studied.
Figure 5. Inhibition of LPS-induced PGE2 production and cytotoxicity
analysis after treatments with first round fractions from a 2006 extract
of E. angustifolia (PI631285) in RAW264.7 cells. The black bars
represent PGE2 levels after induction with 1 μg/mL LPS and treatment
with an Echinacea fraction or ethanol extract (n = 3). All treatments þ
LPS were compared to media þ DMSOþ LPS control that was set at
100% PGE2 production (2.2 ng/mL). Treatments were also performed
without LPS induction showing significant reduction of PGE2 with
fractions 1, 3, 4, and ethanol extract (p e 0.035). The treatments
without LPS were compared to the mediaþDMSO control set at 100%
PGE2 production (0.1 ng/mL). Gray bars symbolize cell survival as
compared to the media þ DMSO control set at 100% cell survival.
Baicalein was used as the positive control in the PGE2 analysis and
showed significant inhibition of PGE2 production (p < 0.0001). ND
indicates analysis not determined. Ursolic acid was used as a positive
control in the cytotoxicity assay and showed significant cell death at 30
and 50 μM (p < 0.0001). Media alone was also used as a negative
control showing no significant inhibition of PGE2 or cytotoxicity. * and **
are representative of p < 0.05 and p < 0.001. Because fraction 3
showed no cytotoxicity at 5 μg/mL, it was not assessed for cytotoxicity
at 1 μg/mL. Each bar represents % of control ( standard error.
8826 J. Agric. Food Chem., Vol. 57, No. 19, 2009 LaLone et al.
conditions (analyzed by GC-MS), instability of bioactivity was
identified with these third round bioactive fractions of E. angusti-
folia. Thus, although these fractions were significantly bioactive
when initially assayed soon after fractionation, in February, 2007,
when these fractions were reassayed for bioactivity when the
synthesis of Bauer alkylamides and ketones became available in
2008, these fractions did not retain the same level of inhibitory
activity in the PGE2 production assay at the concentrations
previously analyzed (Table 4).
DISCUSSION
The study reported here illustrates the important role that
Echinacea alkylamides and ketones play in the inhibition of the
production of inflammatory mediators and the complexities asso-
ciated with the examination of these interacting constituents. The
significant discoveries from the present study are the identification
of Bauer ketones 21 and 23 as potential anti-inflammatory agents
Figure 6. (A) Inhibition of LPS-induced PGE2 production in RAW264.7 cells after treatments with second round fractions from fraction 3 of E. angustifolia (from
Figure 4). The bars represent PGE2 levels after induction with 1 μg/mL LPS and treatment with an Echinacea fraction or ethanol extract (n = 3). All treatmentsþ
LPS were compared to media þ DMSO þ LPS control that was set at 100% PGE2 production (1.8 ng/mL). Treatments were also performed without LPS
induction showing significant reduction of PGE2 with fraction 3 and 3E (pe 0.029). The treatments without LPSwere compared to themediaþDMSOcontrol set
at 100%PGE2 production (0.1 ng/mL). Baicalein and quercetin were used as positive controls. Parallel cytotoxicity screens were conducted yielding no significant
cytotoxicity with any of the fractions (data not shown). * and ** are representative of p < 0.05 and p < 0.001. Each bar represents % of control( standard error.
(B) HPLC chromatograms of second round fractions 3D and (C) 3E, identifying key alkylamides (quantification from HPLC present in Table 2). Black lines
represent 260 nm, and gray lines represent 330 nm. The internal standard used for both partsB andCwasN-isobutylundeca-2-ene-8,10-diynamide (C15H21O2).
Table 2. HPLC Analysis of the Constituents Found in E. angustifolia Fractions
3D and 3Ea
fraction 3D fraction 3E
metabolite concentration metabolite concentration
metabolite μg/mL μM μg/mL μM
Chen alkylamide 2 0.7 0.2 0.0 0.0
Bauer alkylamide 5 2.1 0.5 0.0 0.0
Bauer alkylamide 8 36.6 9.0 0.0 0.0
Bauer alkylamide 9 15.3 3.8 0.0 0.0
Bauer alkylamide 10 0.0 0.0 22.6 5.6
Bauer alkylamide 11 0.1 0.03 37.8 9.5
Bauer alkylamide 14 2.1 0.5 0.0 0.0
Bauer alkylamide 16 0.8 0.2 0.0 0.0
Bauer alkylamide 17 1.7 0.5 0.0 0.0
aHPLC analysis identified alkylamides present in 10 μg/mL of second round
fractions 3D and 3E, as well as the metabolites concentration in micromolar.
Structures of alkylamides have been previously described (2 , 6 ).
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capable of significant inhibition of PGE2 and NO production at
1 μM concentrations and the finding that chemically synthesized
Bauer ketone 23 and Bauer alkylamide 11, when screened for
inhibition of PGE2 production at concentrations present in their
respective E. angustifolia fractions, are capable of inhibiting and
partially explaining the significant PGE2 suppression identified
with their respective plant-derived fractions. Also, Bauer ketones
23 and 24 were identified as key components responsible for the
inhibition of PGE2 identified with E. pallida fraction 3. Another
key observation is that caffeic acid derivatives found in Echinacea
Figure 8. (A) Inhibition of LPS-induced PGE2 production analysis after treatments with E. angustifolia third round D fractions. The black bars represent PGE2
levels after induction with 1 μg/mL LPS and treatment with an Echinacea fraction or ethanol extract (n = 3). All treatmentsþ LPS were compared to mediaþ
DMSO þ LPS control that was set at 100% PGE2 production (2.8 ng/mL). Treatments were also performed without LPS induction showing significant
reduction of PGE2 with fractions 3D, 3D26, 3D27, 3D30, and 3D31 (pe 0.04). The treatments without LPS were compared to the mediaþ DMSO control set
at 100% PGE2 production (0.2 ng/mL). Baicalein was used as a positive control (p < 0.05). Parallel cytoxicity screens were conducted, yielding no significant
cytotoxicity with any of the third round fractions. * and ** are representative of p < 0.05 and p < 0.001. Each bar represents % of control ( standard error.
(B) Inhibition of LPS-induced PGE2 production after treatments withE. angustifolia third round E fractions. The black bars represent PGE2 levels after induction
with 1 μg/mL LPS and treatment with an Echinacea fraction or ethanol extract (n = 3). All treatmentsþ LPSwere compared to mediaþDMSOþ LPS control
that was set at 100% PGE2 production (1.9 ng/mL). Treatments were also performed without LPS induction showing significant reduction of PGE2 with
fractions 3E, 3E33, 3E34, 3E36, 3E37, and 3E38 (pe 0.027). The treatments without LPS were compared to the mediaþ DMSO control set at 100% PGE2
production (0.1 ng/mL). Baicalein was used as a positive control (p < 0.05). Parallel cytotoxicity screens were conducted yielding no significant cytotoxicity with
any of the third round fractions. * and ** are representative of p < 0.05 and p < 0.001. Each bar represents % of control ( standard error.
Figure 7. Combination of Bauer alkylamides 10 and 11 at the concentra-
tions found in fraction 3E (Table 2). The bars represent PGE2 levels after
induction with 1 μg/mL LPS and treatment with an Echinacea fraction (n =
3). All treatmentsþ LPSwere compared tomediaþDMSOþ LPScontrol
that was set at 100% PGE2 production (4.4 ng/mL). Treatments were also
performed without LPS induction showing significant reduction of PGE2
with fraction 3E (p = 0.0275). The treatments without LPS were compared
to the mediaþ DMSO control set at 100% PGE2 production (0.2 ng/mL).
Quercetin was used as the positive control. * and ** are representative of
p < 0.05 and p < 0.001. Each bar represents % of control( standard error.








by dry weight μg μM
3D28 Bauer alkylamides 8-9 18 0.18 0.64
3D32 Bauer ketone 23 75 0.75 0.83
3E33 Bauer alkylamide 10 34 0.34 0.15
Bauer ketone 23 12 0.12 0.25
3E38 Bauer alkylamide 11 87 0.87 3.47
3E40 Bauer alkylamide 11 96 0.96 3.55
aGC-MS analysis identified constituents present in 1 μg/mL of third round
fractions, as well as the metabolites concentration. All identified constituents were
confirmed via synthetic standards.
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are not likely to be key contributors to the inhibition of certain
inflammatory mediators due to the fact that these constituents
were concentrated in fraction 1 of all of the species fractionated,
andnoneof these fractionsdemonstrated the ability to significantly
inhibit PGE2 production at concentrations ranging from 26 to
329 μg/mL.
Ethanol extracts from E. tennesseensis and E. purpurea were
unable to produce fractions capable of inhibiting PGE2 production
to a significant degree at concentrations below5μg/mL.Therefore,
studies on these two species ceased after the first round of
fractionation.
Of the four species screened, E. pallida andE. angustifoliawere
expected to produce the most active fractions because of previous
results (2), indicating that extracts from these plants were in-
hibitory in the PGE2 assay. The fractionation conducted with a
ketone-rich accession of E. pallida provided insight into the anti-
inflammatory potential of ketones found in this species. As
compared to our previous studies that examined chemically
synthesized alkylamides and their ability to inhibit PGE2 produc-
tion (2), it appears that ketones are able to significantly inhibit this
inflammatory end point at a much lower concentration. For
example, the most potent alkylamide (Bauer alkylamide 14) was
reported to significantly inhibit PGE2 production, at a concen-
tration of 10 μM (2), whereas Bauer ketone 23 could do so at a
concentration of 1 μM. Significant cytotoxicity was not identified
for any of the Bauer ketones screened at concentrations below
20 μM, coinciding with a recent cell viability study reporting that
Bauer ketone 21had IC50 values of>100 and 80.13 μMinhuman
pancreatic and colorectal adenocarcinoma cells, respectively (10).
By examining the ability of selected polyacetylenes isolated from
Figure 9. Inhibition of LPS-induced PGE2 production after treatment of synthetic Bauer ketone 23 at a concentration present in third round E. angustifolia
fraction 3D32. The black bars represent PGE2 levels after induction with 1 μg/mL LPS and with the ketone or fraction (n = 3). All treatments þ LPS were
compared to media þ DMSO þ LPS control that was set at 100% PGE2 production (3.8 ng/mL). Treatments were also performed without LPS induction
showing no significant differences in PGE2 production. Quercetin was used as a positive control. * and ** are representative of p < 0.05 and p < 0.001. Each bar
represents % of control ( standard error. A parallel cytotoxicity screen was conducted, yielding no significant cytotoxicity with Bauer ketone 23 at the
concentrations measured (data not shown).
Figure 10. Significant inhibition of LPS-induced PGE2 andNOproduction in RAW264.7 cells after treatment with chemically synthesized Bauer alkylamide 11.
The black bars represent PGE2 levels, and the white bars represent NO levels after induction with 1 μg/mL LPS and treatment with alkylamide (n = 3).
All treatmentsþ LPSwere compared tomediaþDMSOþ LPS control that was set at 100%PGE2 production (4.7 ng/mL) and NO production (11.6 ng/mL).
Treatments were also performed without LPS induction showing no significant differences in PGE2 or NO production. ND indicates that analysis was
not determined. Quercetin was used as a positive control for both studies and showed significant inhibition of PGE2 and NO production at 10 μM (p < 0.0001).
* and ** are representative of p < 0.05 and p < 0.001. Each bar represents% of control( standard error. Parallel cytotoxicity screens were conducted, yielding
no significant cytotoxicity with Bauer alkylamide 11 at the concentrations screened (data not shown).
Table 4. Change in PGE2 Activity over Storage Time with Third Round
E. angustifolia Fractionsa
PGE2 production (% of control)
E. angustifolia fraction August, 2007 June, 2008
3E33 14.1( 6.9** 133.1( 43.5
3E40 18.4( 6.1** 81.0( 3.9
a ** indicates significant p value <0.0001. Bauer alkylamides and ketones
identified to be present in Table 3 were quantified prior to PGE2 analysis in 2007
and again after PGE2 analysis in 2008, yielding no difference in these constituent
concentrations. Data represent % of control( standard error, with 100% of control
for 2007 fractions 3E33 and 3E40 at 1.9 ng/mL and for 2007 fraction 3E33 and 3E40
at 3.5 and 4.7 ng/mL, respectively.
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n-hexane extracts ofE. pallida to cross theCaco-2monolayer, this
study also provided evidence that Bauer ketones 22 and 24 are
likely tobebioavailable, with apparent permeabilities of 3210-6
and 10 10-6 cms-1, respectively (10). Therefore, these results
warrant further elucidation with ketones found in other species of
Echinacea to identify their full anti-inflammatory potential.
Previous studies have shown that Echinacea polyacetylenes,
generically called ketones, were able to modulate the multidrug
transporter P-glycoprotein (Pgp), which bestows resistance to
anticancer chemotherapy when highly expressed in cancer cells.
In a human kidney cell line (HK-2), made to constitutively
overexpress high and constant levels of Pgp, it was determined
through a bioassay-guided fractionation of an E. pallida extract
that Bauer ketone 24 decreased the efflux of the Pgp probe
calcein-AM by 3-fold as compared to the control at a concentra-
tion of 30 μM (21). To our knowledge, there are no reports
regarding the anti-inflammatory potential of the Bauer ketones;
yet, there are studies describing anti-inflammatory effects of
polyacetylenes in other species. For example, polyacetylenes of
Daucus carota L. have been shown to inhibit LPS-induced NO
production in the RAW264.7 macrophage cell line (22), and
polyacetylene spiroketals from Plagius flosculosus have been
identified to inhibit LPS-induced IL-1, IL-6, TNF-R, and PGE2
production aswell as to inhibit the degradation of IkB and further
DNA binding of NF-kB (23).
E. angustifolia, classified as one of the three Echinacea medic-
inal species, has been featured in other studies due to its
alkylamide-rich composition (2,24,25). The first round ofHPLC
fractionation of the ethanol extract of E. angustifolia yielded one
fraction, fraction 3, which inhibited PGE2 production by 51.1%
of control at a concentration of 1 μg/mL, therefore establishing a
rationale for additional fractionation. Results from the second
round of HPLC fractionation yielded two fractions, fractions 3D
and 3E, which significantly inhibited PGE2 production. Multiple
alkylamides were identified in fraction 3D, which made this
fraction an excellent candidate for further fractionation.
HPLC analysis of fraction 3E indicated the occurrence of two
highly abundant alkylamides, Bauer alkylamides 10 and 11,
which had previously been chemically synthesized for our stu-
dies (2).Wehypothesized thatBauer alkylamides 10 and 11, when
combined at concentrations similar to those found in fraction 3E,
could explain the fractions PGE2 inhibitory capabilities. Syn-
thetic Bauer alkylamides 10 and 11 individually were capable of
significant inhibition of PGE2 production at concentrations of
5.6 and 9.5 μM, respectively. However, the combination of
synthesized Bauer alkylamides 10 and 11 at concentrations
present in fraction 3E could not explain fraction 3E’s PGE2
inhibitory capabilities. Previous studies in our lab found that
individually, chemically synthesized Bauer alkylamides 10 and 11
were not capable of significant PGE2 inhibition at concentrations
lower than 50 μM.We attribute this significant change in activity
to a couple of modifications in our screening protocol. The first
major change was using optimal growth conditions for the
RAW264.7 cells by setting the incubation humidity to 95% as
opposed to our previous studies that used 70%humidity. Second,
in the current study, we analyze each chemically synthesized
preparation prior to its use as an inhibitor of PGE2 production,
allowing for impurities in the alkylamide preparations and
normalizing to a concentration at 100% purity; this normal-
izationwas not conducted in our previous studies of the inhibition
of PGE2 production. These changes have therefore allowed for
greater sensitivity in our screening of inflammatory mediators
using the RAW264.7 mouse macrophage cell line.
GC-MS analysis of the third round of HPLC fractions of
E. angustifolia identified Bauer ketone 23 to be present in two of
these fractions; fraction 3D32 contained Bauer ketone 23 at a
concentration of 0.83 μM and several other unidentifiable peaks.
To our knowledge, this is the first study to identify the presence of
Bauer ketone 23 in E. angustifolia. Bauer ketone 23 partially
explained the inhibition of PGE2 production observed with
fraction 3D32 (44.9% of control) and can therefore be identified
as a key constituent contributing to the immune-modulating
properties of E. angustifolia and perhaps other species. Chemi-
cally synthesized Bauer alkylamide 11 showed significant inhibi-
tion of PGE2 and NO production at the concentration that this
alkylamide occurs in fraction 3E40. Although this constituent
appeared to account for approximately 96% of the mass that
occurred in this fraction, it only partially explained the PGE2
inhibition observed with its respective fraction. Through these
studies, Bauer alkylamide 11 of E. angustifolia was identified as
another key contributor to the suppression of PGE2 and NO.
This alkylamide was shown to have bioactivities at concentra-
tions relevant to those found in the plant extracts and contributed
to anti-inflammatory properties throughout an inflammatory
response measured via PGE2 production at 8 h and NO produc-
tion at 24 h after induction with LPS to induce the mouse
macrophage cells. Chen et al. previously identified Bauer alkyl-
amide 11 as an inhibitor ofNOproduction in theRAW264.7 cells
with an ID50 of 23.9 μM (3), and our studies add to this by
determining that inhibition of NO production can be accom-
plished at alkylamide concentrations available in E. angustifolia.
Two main observations from these studies have led us to the
hypothesis that other unidentified constituents found in Echinacea
are critical components to the anti-inflammatory potential of this
botanical. First, we have demonstrated that individually Bauer
alkylamides and ketones can significantly inhibit PGE2 and NO
production but only partially explain the activity found in the
fractions from the species. Also, when known constituents were
combined at concentrations relevant to extracts and partially
purified fractions, therewas no evidence of an additive or synergistic
effect on the inhibition of PGE2 or NO production. Second,
although the concentrations of Bauer alkylamides 10 and 11 and
Bauer ketone 23 did not change over storage time throughout our
studies, themost convincing argument for this hypothesis developed
through the instability thatweobserved throughout our studieswith
the bioactivity of E. angustifolia third round fractions. Significant
inhibition of PGE2 production was lost after storing selected third
round fractions at -20 C for approximately 1 year, without any
significant decrease in the concentrations of Bauer alkylamides and
ketones. These observations provide evidence to the hypothesis that
other unstable constituents contribute to the identified inhibition of
PGE2 production.
In summary, this research confirmed our previous studies that
E. angustifolia and E. pallida are important species of Echinacea
for discovering the anti-inflammatory properties of this botanical
genus and further allowed for the identification of constituents that
are key contributors to those properties. From the fractionations
of E. pallida and E. angustifolia extracts, two major compounds,
Bauer alkylamide 11 andBauer ketone 23, were identified to play a
key role in the inhibition of PGE2 by RAW264.7 mouse macro-
phage cell model. These constituents were also identified as
inhibitors of NO production, indicating that they are important
mediators for an extended period throughout the inflammatory
response. The analysis of Bauer ketone 23 at the concentration
present in fraction 3D32 and of Bauer alkylamide 11 at the
concentration present in fraction 3E40 indicates that more studies
should be directed toward the identification and synthesis of
known and unknown compounds and the roles they may play,
either individually or in concert with known constituents, to
modulate mediators of the inflammatory response.
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The results obtained from this study may pave the way for the
production of Echinacea species that are better suited for anti-
inflammatory medicinal purposes. These could be produced
through the fabrication of genetically modified plants, the detec-
tion of other plant organs and tissues that are rich in specific
constituents, or the identification of optimal growth conditions
for the enhanced availability of constituents such as Bauer
ketones 21, 23, and 24 and Bauer alkylamides 10 and 11.
ABBREVIATIONS USED
E., Echinacea; PI, plant introduction; DMSO, dimethyl sulf-
oxide; PGE2, prostaglandin E2; NO, nitric oxide; LPS, lipopoly-
saccharide; GC-MS, gas chromatography-mass spectrometry;
HPLC, high-performance liquid chromatography; ID50, inhibi-
tion dose producing 50% inhibition.
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